KALEIGH FOSTER: Open Payments
NPI 1730660010 · TEXARKANA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,410 in 49 payments from 10 companies in 2025. Trend: 2023 $1,280 · 2024 $1,332 · 2025 $1,410
Food & beverage: $1,320Education: $90
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 16 | $423 |
| Regeneron Healthcare Solutions, Inc. | 12 | $315 |
| United Therapeutics Corporation | 4 | $210 |
| Actelion Pharmaceuticals US, Inc. | 4 | $209 |
| Verona Pharma, Inc. | 5 | $92 |
| GlaxoSmithKline, LLC. | 3 | $58 |
| Viatris Specialty LLC | 1 | $34 |
| Insmed, Inc. | 2 | $30 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Amgen Inc. | 1 | $17 |
Products named: DUPIXENT, BREZTRI, Tyvaso, UPTRAVI, TEZSPIRE, Ohtuvayre, FASENRA, OPSUMIT.
Industry payments across TX — which companies pay providers there.
